Scinai Immunotherapeutics (Scinai Immunotherapeutics) Investments And Advances : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Investments And Advances?

Scinai Immunotherapeutics's Investments And Advances for the quarter that ended in Sep. 2023 was $0.00 Mil.

Scinai Immunotherapeutics Investments And Advances Historical Data

The historical data trend for Scinai Immunotherapeutics's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Investments And Advances Chart

Scinai Immunotherapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Investments And Advances

Get a 7-Day Free Trial

Scinai Immunotherapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Scinai Immunotherapeutics Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

2F50:Germany

Address

Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR

Website

https://www.biondvax.com

BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.

Executives

Samuel J Moed	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain	director, other: Chairman	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Chief Financial Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin	director	4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv	director	STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster	director	11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia	officer: Chief Scientist	6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman	director	21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman	director, officer: Chief Executive Officer	269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark	officer: Chief Operating Officer	27 HAILANOT, HERZLIYA L3 4631214
George Lowell	director	33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green	director	354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6